In this section
Clinical trials
- Participate in a clinical trial
- For medical professionals
- Active clinical trials for pediatric cancers
- Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study
- Blinatumomab bridging therapy in high-risk B-ALL clinical trial
- CAR-20/19-T cells in pediatric and young adult patients with relapsed/refractory B Cell Acute Lymphoblastic Leukemia (CAR-20/19-T) phase 1 clinical trial
- Unrelated and partially matched related donor peripheral stem cell transplantation for patients with hematologic malignancies clinical trial
- Early stage research
Active clinical trials
Clinical Trials - Diseases by specialty group
Solid Tumors 14
-
Protocol ID
- Associated disease
- Title
-
COG-ADVL1412
- Ewing Sarcoma
- A Phase 1/2 Study of Nivolumab (Ind# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
-
COG-ADVL1414
- Ewing Sarcoma
- A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
-
COG-ADVL1921
- Ewing Sarcoma
- Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
-
COG-AEWS1221
- Ewing Sarcoma
- Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
-
COG-APEC1621A
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions
-
COG-APEC1621B
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations
-
COG-APEC1621D
- Ewing Sarcoma
- NCI-COG PEDIATRIC MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
-
COG-APEC1621E
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Selumetinib (Azd6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
-
COG-APEC1621F
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations
-
COG-APEC1621H
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes
-
COG-APEC1621I
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
-
COG-APEC1621K
- Ewing Sarcoma
- NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
-
COG-APEC1621SC
- Ewing Sarcoma
- NCI - COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
-
SPOC-2012-001
- Ewing Sarcoma
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
Contact us
For more information about cancer and blood disorders clinical trials, email us or call
(414) 955-4727
Get a second opinion
It's important to know what your options are. We can provide expert opinions to verify or give more information about an initial diagnosis. Contact us today.
Why participate in clinical trials?
